Although it was not possible to assess prognosis in one patient, SMARCB1 may also predict immune checkpoint blockade responsiveness independently, which supports the notion that SMARCB1 deficiency may represent a primary event rather than a secondary phenomenon in MSI-associated carcinoma. Here, SMARCB1 is linked to carcinoma.